Simply months after its acquisition by personal fairness fund Astorg, the French specialist in biotech energetic elements and diagnostic kits for the wonder, pharmaceutical, nutraceutical and biotechnology sectors has carried out three consecutive acquisitions.
Following final month’s acquisition of Mibelle Biochemistry, a Swiss specialist in high-performance beauty energetic elements, Solabia has introduced two new offers: the acquisition of Seqens’ botanical energetic elements and in vitro diagnostics enterprise, and the acquisition of Xebios Diagnostics Group, a microbiological diagnostics resolution supplier with operations in Germany and the Netherlands.
Excessive efficiency botanical energetic elements
Centered on the event and manufacturing of high-performance plant-based energetic elements for cosmetics, in addition to plasmas and serums for diagnostic purposes, Seqens’ Botanical Actives and In Vitro Diagnostics (IVD) enterprise operates from a website in Limoges, France (previously ID bio Novacap), recognized for its superior botanical extraction and high-end manufacturing capabilities. Its elements and diagnostic options are marketed worldwide and utilized by main manufacturers throughout the cosmetics and pharmaceutical industries.
Via this operation, Solabia reinforces its international place as a number one provider of excessive efficiency substantiated botanical energetic elements for cosmetics purposes, whereas additionally securing a important uncooked materials provide for its diagnostics actions.
Microbiological testing
For its half, the acquisition of Xebios Diagnostics Group, which has constructed a robust status in diagnostic tradition media and reagents for the evaluation of ingesting water, meals and drinks, cosmetics and scientific samples, permits Solabia to considerably reinforce and develop its European diagnostics footprint and actions, whereas strengthening its manufacturing base throughout France, Germany, and the Netherlands.
“This acquisition marks a major step in our ambition to construct a number one European diagnostics platform,” mentioned Jean-Baptiste Dellon, CEO of Solabia.
After buying PolymerExpert in 2024, these three new acquisitions are set to push Solabia’s income near EUR 250 million.
